| Eric Terhaerdt |
Eric Terhaerdt is currently the Senior Vice President-Development Operations at Cytokinetics, Inc. He previously worked as the Vice President-Clinical United States at AstraZeneca Pharmaceuticals LP and as the Senior VP-Global Development Operations at Astellas US LLC. Mr. Terhaerdt completed his undergraduate degree at The University of Waterloo and holds an MBA from the University of Warwick. |
| Fady Ibraham Malik |
Fady Ibraham Malik is currently an Independent Director at Rocket Pharmaceuticals, Inc. He also holds the position of Executive Vice President-Research & Development at Cytokinetics, Inc. Additionally, he is a Professor at The University of California, San Francisco and the Veterans Administration Medical Center. Dr. Malik has an undergraduate degree from the University of California, Berkeley and a doctorate degree from The University of California, San Francisco. |
| Daniel R. Casper |
Daniel R. Casper is currently the Vice President-Information Technology at Cytokinetics, Inc. He completed his undergraduate degree at the University of Virginia and his graduate degree at Stanford University. |
| Robert C. Wong |
Robert C. Wong is currently the Chief Accounting Officer & Vice President at Cytokinetics, Inc. He previously worked as the Chief Accounting Officer & Controller at Genentech, Inc. and as an Audit Manager at Ernst & Young LLP. Wong received his undergraduate degree from the University of California, Berkeley. |
| Stuart Kupfer |
Stuart Kupfer is currently the Chief Medical Officer & Senior Vice President at Cytokinetics, Inc. Prior to his current position, he worked as the Vice President & Head-Therapeutic Area at Takeda Pharmaceuticals U.S.A., Inc. from 2004 to 2016. He also has a doctorate degree from the University of Florida. |
| Andrew Callos |
Mr. Andrew Callos is a Chief Commercial Officer & Executive VP at Cytokinetics, Inc. Mr. Callos was previously employed as a Vice President-US Cardiology & Metabolic Marketing by Pfizer Inc. and an Assistant Vice President-Marketing by Wyeth Pharmaceuticals, Inc. He received his undergraduate degree from Drexel University. |
| Kari K. Loeser |
Kari K. Loeser is currently the Chief Compliance Officer & VP at Cytokinetics, Inc. Prior to this, she held positions as the Senior Director & Senior Compliance Counsel at Jazz Pharmaceuticals, Inc. and as the Senior Corporate Counsel & Privacy Officer at Vifor Pharma, Inc. She completed her undergraduate degree at the University of Iowa and her graduate degree at DePaul University College of Law. |
| Steven M. Cook |
Steven M. Cook is currently working as the SVP-Global Supply Chain & Technical Operations at Cytokinetics, Inc. He started this position in 2021. Prior to his current job, he obtained an undergraduate degree from Towson University. |
| Stephen B. Heitner |
Stephen B. Heitner is currently working as the VP-Clinical Research & Head-Therapeutic Area at Cytokinetics, Inc. He previously worked as an Associate Professor at Oregon Health & Science University. He holds a doctorate degree from the University of the Witwatersrand. |
| John Tannahill Henderson |
Dr. John T. Henderson, MD, is a Chairman at Cytokinetics, Inc. Dr. Henderson was previously employed as an Independent Director by Myrexis, Inc., an Independent Director by Myriad Genetics, Inc., a President by Futurepharm LLC, a Chairman by Asmacure Ltée, a Non-Executive Director by Inveresk Research Group, Inc., a Chief Development Officer by NeuroVia, Inc., a VP-Europe, US & International Pharmaceuticals by Pfizer Inc., and a Vice President by Pfizer Pharmaceuticals, Inc. He received his undergraduate degree from The University of Edinburgh and a doctorate degree from The University of Edinburgh. |
| Robert I. Blum |
Robert I. Blum is currently the President, CEO, CFO & Director at Cytokinetics, Inc. He is also a Director at Life Science Cares Bay Area, The Jewish Family & Children's Services, Temple Emanu-El, and a Member-American Committee at the Weizmann Institute of Science. Previously, he served as the Chairman at Gamida Cell Ltd. from 2018 to 2023 and as the Marketing Director at COR Therapeutics, Inc. from 1991 to 1998. He has also held positions as a Director at the Anti-Defamation League, The Bay Area Bioscience Association, Jewish Community Federation of San Francisco, and The Contemporary Jewish Museum. Mr. Blum completed his undergraduate studies at Stanford University and holds an MBA from Harvard Business School. |
| Robert A. Harrington |
Robert A. Harrington is currently an Independent Director at Cytokinetics, Inc. He is also a Director at SignalPath LLC. In addition, he holds the position of Director at American Heart Association, Inc., Scanadu, Inc., HealthPals, Inc., Association of American Physicians, Association of University Cardiologists, and THE STEPHEN & SUZANNE WEISS FOUNDATION, INC. Previously, Dr. Harrington served as the Chairman-Medicine Department & Professor at Stanford University School of Medicine. He was also the Director & Professor at Duke Clinical Research Institute and Director at Stanford Health Care. Additionally, he held the position of Trustee at American College of Cardiology Foundation and was a Member of The Institute of Medicine of Chicago and the National Academy of Medicine (United States). Dr. Harrington completed his undergraduate degree at the College of the Holy Cross (Massachusetts) and obtained his graduate degree from Tufts University School of Medicine. |
| Nancy J. Wysenski |
Nancy J. Wysenski was the founder of EMD Pharmaceuticals, Inc. founded in 1999, where she held the position of President & Chief Executive Officer from 2001 to 2006. Currently, she holds the position of Director at Alkermes, Inc. since 2013, Independent Director at Cytokinetics, Inc. since 2020, and President-Research Triangle Park Chapter at Healthcare Businesswomens Association. In the past, she has worked as a Director at North American Scientific, Inc. and Reata Pharmaceuticals, Inc. She was also an Independent Director at Tetraphase Pharmaceuticals, Inc. from 2014 to 2020, Inovio Pharmaceuticals, Inc. from 2015 to 2017, and Dova Pharmaceuticals, Inc. from 2018 to 2019. She held the position of Lead Independent Director at Alkermes Plc from 2022 to 2023. She was the Chief Operating Officer at Indevus Pharmaceuticals, Inc. in 2009 and the Chief Commercial Officer & Executive VP at Vertex Pharmaceuticals, Inc. from 2011 to 2012. She was also the Chief Operating Officer at Endo Health Solutions, Inc. from 2007 to 2009 and at Endo Pharmaceuticals, Inc. from 2007 to 2009. She held the position of Senior Vice President-Operations at NetGenics, Inc. She was a Vice President-Field Sales at Astra Merck, Inc. from 1984 to 1998. She is a Trustee at North Carolina Central University. She holds an MBA from Baldwin-Wallace College and an undergraduate degree from Kent State University (Ohio). |
| Sandford D. Smith |
Sandford D. Smith founded Global Biolink Partners in 2011, where he is working as Chairman from 2011. Mr. Smith also currently works at Cytokinetics, Inc., as Independent Director from 2012 and Tullis Health Investors, Inc., as Operating Partner from 2013. Mr. Smith also formerly worked at Repligen Corp., as President, Chief Executive Officer & Director from 1986 to 1996, ARIAD Pharmaceuticals, Inc., as Vice Chairman from 1991 to 2008, Aegerion Pharmaceuticals, Inc., as Chairman in 2016, Novelion Therapeutics, Inc., as Vice Chairman from 2016 to 2017, Apricus Biosciences, Inc., as Independent Director from 2014 to 2019, Nventa Biopharmaceuticals Corp., as Director from 2007 to 2009, BioBehavioral Diagnostics Co., as Director, Seneca Biopharma, Inc., as Independent Director from 2014 to 2020, Boston Philharmonic Orchestra, as Director, Akcea Therapeutics, Inc., as Independent Director from 2017 to 2020, Bristol Myers Squibb Co., as VP-Business Development & Strategic Planning from 1977 to 1986, Genzyme Corp., as President-International Group & Executive VP in 2011, The Brigham & Women's Hospital, Inc., as Trustee, Genzyme Therapeutics Ltd., as President from 1996 to 2011, and Genzyme International, as President. Mr. Smith received his undergraduate degree from the University of Denver. |
| Muna Bhanji |
Muna Bhanji is the founder of TIBA Global Access LLC, founded in 2021, where she holds the title of President. She currently holds multiple positions as an Independent Director at Cytokinetics, Inc., Veracyte, Inc., Ardelyx, Inc., and Intellia Therapeutics, Inc. She is also a Director at Corus International Ltd. and Lumanity, Inc. (United States). Additionally, she holds the position of Senior Advisor & Advisory Board Member at Arsenal Capital Management LP, and is a Board Member at Women Business Leaders of the US Health Care Industry Fnd and Womencorporatedirectors Foundation. Ms. Bhanji has held former positions as a Director at AMCP Foundation and Possible Health. She was also a Senior VP-Global Market Access & Policy at Merck & Co., Inc. from 1986 to 2020. Ms. Bhanji has a Master's in Business Administration from St. Joseph's University and an undergraduate degree from the Ernest Mario School of Pharmacy. |
| Edward M. Kaye |
Dr. Edward M. Kaye, MD, is an Independent Director at Avidity Biosciences, Inc., a Chief Executive Officer & Director at Stoke Therapeutics, Inc., an Independent Director at Cytokinetics, Inc. and an Advisory Board Member at CureDuchenne Ventures LLC. He is on the Board of Directors at Avidity Biosciences, Inc., Stoke Therapeutics, Inc., Cytokinetics, Inc. and Massachusetts Biotechnology Council. Dr. Kaye was previously employed as an Independent Director by NeuroVia, Inc., a Group Vice President-Clinical Development by Genzyme Corp., a Chief-Biochemical Genetics by The Children's Hospital of Philadelphia, a Chief-Neurology by St. Christopher's Hospital for Children LLC, and an Associate Professor by Perelman School of Medicine. He also served on the board at Sarepta Therapeutics, Inc. He received his undergraduate degree from Loyola University New Orleans and a doctorate degree from Stritch School of Medicine. |
| Santo J. Costa |
Santo J. Costa is currently the Chairman at Aquestive Therapeutics, Inc. and the Chairman at The North Carolina Biotechnology Center. He is also an Independent Director at Cytokinetics, Inc., a Director at Holzworth Holdings, Inc., and Of Counsel at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP. Additionally, he is a Member at Fortsum Business Solutions, Inc., a Member at The North Carolina Bar Association, and a Trustee at Ravenscroft School, Inc. In the past, Mr. Costa served as the Vice Chairman, President & Chief Operating Officer at Quintiles Transnational Corp. He was also the Non-Executive Chairman at ArgoMed, Inc., the Chairman at Labopharm, Inc., the Non-Executive Chairman at The Sustainable Nutrition Group Pty Ltd., and the Chairman at Metabolon, Inc. He held the position of Chairman at BioPheresis Technologies, Inc. and served as a Director at Bausch Health Americas, Inc., OSI Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., CV Therapeutics, Inc., NeuroMedix, Inc., Biovest Corp. I, DigiScript, Inc., Magor Corp., Maupin Taylor PA, Williams Mullen PC, Glaxo, Inc., Merrell Dow Pharmaceuticals, Inc., and Norwich Eaton Pharmaceuticals, Inc.Mr. Costa obtained his undergraduate and graduate degrees from St. John's University in 1968 and 1971, respectively. |
| Wendell D. Wierenga |
Wendell D. Wierenga is currently serving as the Chairman at Crinetics Pharmaceuticals, Inc. since 2015. He is also an Independent Director at Cytokinetics, Inc. since 2011 and an Independent Director at Dermata Therapeutics, Inc. since 2016. In his former positions, Dr. Wierenga served as the Chief Executive Officer at Syrrx, Inc. from 2000 to 2003. He held the position of Executive Director-Discovery Research at Pharmacia & Upjohn, Inc. He also served as the Executive Director-Discovery Research at The Upjohn Co. from 1974 to 1990. Dr. Wierenga was an Independent Director at Onyx Pharmaceuticals, Inc. from 1996 to 2013. He served as an Independent Director at Apricus Biosciences, Inc. from 2014 to 2019. Additionally, he held the position of Director at Aspira Women's Health, Inc., Concert Pharmaceuticals, Inc., Patara Pharma LLC, and SRI International. Dr. Wierenga was an Independent Director at XenoPort, Inc. from 2000 to 2016. He served as an Independent Director at OCERA Therapeutics LLC from 2013 to 2017 and at Anacor Pharmaceuticals LLC from 2014 to 2016. He was the Vice President-Medtech Ventures at Warner-Lambert Co. from 1992 to 2000. Dr. Wierenga also served as the Executive Vice President-Research & Development at Neurocrine Biosciences, Inc. from 2003 to 2006, at Santarus, Inc. from 2011 to 2014, and at Ambit Biosciences Corp. from 2007 to 2011. He held the position of Senior Vice President-Research at Parke-Davis Pharmaceutical Research, Inc. from 1990 to 2000. He was also the Senior VP-Worldwide Pharmaceutical Sciences at Pfizer Inc. from 1990 to 2000. Dr. Wierenga obtained a doctorate degree from Stanford University and an undergraduate degree from Hope College. |
| B. Lynne Parshall |
Ms. B. L. Parshall is an Independent Director at Foghorn Therapeutics, Inc., a Chief Executive Officer at Pinnacle Consulting LLC, an Independent Director at Cytokinetics, Inc., a Member at American Bar Association, a Member at Licensing Executives Society, a Member at San Diego County Bar Association and a Member at The State Bar of California. She is on the Board of Directors at Foghorn Therapeutics, Inc., Ring Therapeutics, Inc., Repertoire Immune Medicines, Inc., Cytokinetics, Inc. and Ionis Pharmaceuticals, Inc. Ms. Parshall was previously employed as a Chairman by Akcea Therapeutics, Inc. and a Partner by Cooley LLP. She also served on the board at Regulus Therapeutics, Inc., CardioDynamics International Corp. and Corautus Genetics, Inc. She received her undergraduate degree from Harvard College and a graduate degree from Stanford Law School. |
